Bristol-Myers Squibb Company (BMY)
Financial leverage ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 92,603,000 | 95,159,000 | 96,820,000 | 109,314,000 | 118,481,000 |
| Total stockholders’ equity | US$ in thousands | 16,335,000 | 29,430,000 | 31,061,000 | 35,946,000 | 37,822,000 |
| Financial leverage ratio | 5.67 | 3.23 | 3.12 | 3.04 | 3.13 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $92,603,000K ÷ $16,335,000K
= 5.67
The financial leverage ratio for Bristol-Myers Squibb Company has shown a slight fluctuation over the years. As of December 31, 2020, the ratio stood at 3.13, which decreased to 3.04 by the end of 2021 before slightly increasing to 3.12 by the end of 2022. However, there was a more significant increase to 3.23 by the end of 2023, indicating a potential increase in financial leverage. The ratio then spiked to 5.67 by the end of 2024, suggesting a substantial increase in leverage compared to the previous years. Overall, the trend in the financial leverage ratio demonstrates some variability, with a notable spike in 2024, which may warrant further investigation into the company's debt management and capital structure strategies.
Peer comparison
Dec 31, 2024